MedPath

Sigma Tau I.f.r S.p.a.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:2
Completed:11

Trial Phases

3 Phases

Phase 1:5
Phase 2:6
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (42.9%)
Phase 1
5 (35.7%)
Phase 3
3 (21.4%)

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Phase 1
Terminated
Conditions
Skin Neoplasm
Pancreatic Neoplasm
Digestive System Neoplasm
Connective and Soft Tissue Neoplasm
Head and Neck Neoplasm
Respiratory Tract Neoplasm
Urogenital Neoplasm
Breast Neoplasm
Lymphoma, Non-Hodgkin
First Posted Date
2015-11-11
Last Posted Date
2018-09-18
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
2
Registration Number
NCT02602067
Locations
🇫🇷

Institut Bergonnie, Bordeaux, France

🇫🇷

Centre Leon Berard, Lyon, France

🇫🇷

Icm Val D'Aurelle, Montpellier, France

and more 4 locations

A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria

Phase 2
Completed
Conditions
Malaria,Falciparum
Interventions
Drug: Eurartesim dispersible oral tablet
Drug: eurartesim film coated tablet
First Posted Date
2013-11-25
Last Posted Date
2016-11-08
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
300
Registration Number
NCT01992900
Locations
🇧🇫

Centre Muraz, Bobo Dioulasso, Burkina Faso

🇧🇫

Centre National de Recherche et de Formation en Paludisme, Ouagadougou, Burkina Faso

🇨🇩

Kinshasa School of Public Health, School of Medicine, University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the

and more 4 locations

ST1968 Intravenous (Weekly) in Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2012-12-12
Last Posted Date
2012-12-12
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
62
Registration Number
NCT01748019

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Phase 3
Terminated
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2012-03-30
Last Posted Date
2016-11-06
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
150
Registration Number
NCT01567956
Locations
🇦🇹

Landeskrankenhaus-Universitätskliniken Innsbruck - Klinische Abteilung für Gastroenterologie und Hepatologie, Innsbruck, Austria

🇦🇹

Krankenhaus der Barmherzigen Brüder - Abteilung für Innere Medizin, Salzburg, Austria

🇦🇹

Ordinationszentrum Döbling, Vienna, Austria

and more 55 locations

Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis

Phase 3
Terminated
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2012-02-24
Last Posted Date
2016-11-06
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
147
Registration Number
NCT01538251
Locations
🇧🇪

Imelda Ziekenhuis, Bonheiden, Antwerpen, Belgium

🇧🇪

Universitaire Ziekenhuis Gasthuisberg, Leuven, Flemish Brabant, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium

and more 55 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.